
Opinion|Videos|March 14, 2025
Navigating RCC Progression: Optimizing Treatment Sequence After the First Line
Experts discuss emerging patterns of progression with current frontline regimens for advanced renal cell carcinoma (RCC), differences between immunotherapy (IO)/IO and IO/tyrosine kinase inhibitor (TKI) combinations, and how these progression patterns impact prognosis and subsequent therapy selection, considering whether the patient received IO/IO or IO/TKI in the first line and the clinical factors influencing later-line treatment decisions.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- In your experience, what patterns of progression are emerging with current frontline regimens for advanced RCC, and are there notable differences between IO/IO and IO/TKI combinations? How do these progression patterns—such as common sites of progression or timing—impact prognosis and influence your choice of subsequent therapy?
- When a patient progresses on frontline therapy, how do you approach treatment selection in the later-line setting?
- Does your choice differ based on whether the patient received IO-IO or IO-TKI in the first line? What clinical and disease-specific factors most influence your decision?
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Leighl on HARMONi Survival Data and the FDA's Decision on Ivonescimab in Previously Treated EGFR-Mutated NSCLC
5



